Spark Therapeutics (NASDAQ: ONCE) and Roche announced today the completion of Roche’s acquisition of Spark following the receipt of regulatory approvals from all government authorities required by the merger agreement. The Goodwin team advised Spark on this acquisition.
Roche is acquiring Spark at a price of $114.50 per share in an all-cash transaction. Spark will continue its operations in Philadelphia as an independent company within the Roche Group.
Spark Therapeutics is a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease. The company has successfully applied its technology in the first gene therapy approved in both the U.S. and EU for a genetic disease, and currently have four programs in clinical trials, including product candidates that have shown promising early results in patients with hemophilia.
The Goodwin team was led by partners Stuart Cable, Lisa Haddad, Blake Liggio, Deborah Birnbach.
For additional details on the completion of the acquisition, please read the press release.